Morgan Stanley Maintains Equal-Weight on Axsome Therapeutics, Raises Price Target to $249
Benzinga Newsdesk 7 hours ago
Analyst RatingsNewsPrice Target
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $247 to $249.
Morgan Stanley analyst Sean Laaman maintains Axsome Therapeutics (NASDAQ:AXSM) with a Equal-Weight and raises the price target from $247 to $249.